Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jakšić, Petra"'
Autor:
Linarić, Petra, Pavlović Mavić, Mirjana, Mirčevski, Karla, Meštrović, Josipa, Jakšić, Petra, Tečić Vuger, Ana, Vazdar, Ljubica, Šeparović, Robert
Results of our research showed that there was no statistically significant difference in duration of treatment between patients with luminal and non-luminal subtype, same as was reported in CLEOPATRA trial. Analyzing correlation between duration of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::589e85c6a0cd9d7be0fd18de0b51fe36
https://www.bib.irb.hr/1274029
https://www.bib.irb.hr/1274029
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tečić Vuger, Ana, Perić Balja, Melita, Jakšić, Petra, Linarić, Petra, Pavlović Mavić, Mirjana, Vazdar, Ljubica, Šeparović, Robert
Neoadjuvant, i.e. preoperative, systemic antineoplastic treatment (NAT), in patients with breast cancer enables in vivo monitoring of tumor response to applied therapy, tailoring treatment in real –time accordingly, sparing surgical procedures, bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::de798104747bb8dff63770095b3df808
https://www.bib.irb.hr/1260825
https://www.bib.irb.hr/1260825
Autor:
Pavlović Mavić, Mirjana, Šeparović, Robert, Vazdar, Ljubica, Tečić Vuger, Ana, Jakšić, Petra, Linarić, Petra
Liver is the most common site of metastases from CRC.Surgical resection is the only treatment that offers a chance of long-term survival, however, only a minority of patients is suitable for upfront surgery. In patients with initially unresectable li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::9b62f547cfa24924392587a5c5aa9e4a
https://doi.org/10.1016/j.annonc.2022.04.287
https://doi.org/10.1016/j.annonc.2022.04.287
Autor:
Linarić, Petra, Mirčevski, Karla, Vazdar, Ljubica, Tečić Vuger, Ana, Jakšić, Petra, Popović, Josipa, Trajbar, Mihaela, Pavlović Mavić, Mirjana, Šeparović, Robert
Osnova liječenja HER2-pozitivnog proširenog raka dojke je kombinacija HER2 blokade i kemoterapije. U metastatskom okruženju, osim učinkovitosti, od primarne su važnosti nuspojave liječenja i kvaliteta života (eng. QoL) bolesnika. U liječenju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::0ec2905101b36803ad2766a893155837
https://www.bib.irb.hr/1262979
https://www.bib.irb.hr/1262979
Autor:
Linarić, Petra, Tečić Vuger, Ana, Pavlović Mavič, Mirjana, Vazdar, Ljubica, Jakšić, Petra, Šeparović, Robert
First-line treatment with pertuzumab/trastuzumab/docetaxel significantly improved overall survival for patients with HER2-positive metastatic breast cancer compared with placebo/trastuzumab/docetaxel. Our question is whether there is a statistically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::76edf61a0a97fbbe949ec23b2483edac
https://www.bib.irb.hr/1264316
https://www.bib.irb.hr/1264316
Autor:
Jakšić, Petra
Grupni programi pripadaju skupini redovnih oblika vježbanja te u svojoj ponudi imaju široki spektar programa za vježbače bez obzira na njihovo predznanje, dob, spol i razinu motoričkih i funkcionalnih sposobnosti. Cilj ovog rada bio je utvrditi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4117::437595ca71a17dc71236a0a6dc9de220
https://urn.nsk.hr/urn:nbn:hr:221:750283
https://urn.nsk.hr/urn:nbn:hr:221:750283
Autor:
Jakšić, Petra
Cilj: Glavni cillj ovog istraživanja je odrediti učinak Tempol-a na protokom potaknutu dilataciju kod Sprague-Dawley štakora na terapiji Losartanom. Materijali i metode: U istraživanje su bili uključeni zdravi muški Sprague-Dawley (SD) štakori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::43b9c609366ff059eb1675434d4e300a
https://www.bib.irb.hr/1032366
https://www.bib.irb.hr/1032366